Phase I / II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Documenti analoghi

• Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia
  di: Kai Wille, et al.
  Pubblicazione: (2024)
• Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia
  di: Graeme F. Murray, et al.
  Pubblicazione: (2024)
• An Overview of Chronic Myeloid Leukemia Treatment: From Tyrosine Kinase Inhibitors to Novel and Emerging Therapies
  di: Akash Joel Sekar, et al.
  Pubblicazione: (2026)
• Correction to “Venetoclax‐Based Therapy for Relapsed or Refractory Acute Myeloid Leukaemia Following Intensive Induction Chemotherapy”
  Pubblicazione: (2025)
• Comparison of HiDAC Versus FLAG‐IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High‐Risk Myelodysplastic Syndrome
  di: Man Wai Tang, et al.
  Pubblicazione: (2024)